Adaptimmune Therapeutics (ADAP)

Adaptimmune Therapeutics (ADAP) Financial Statements


Adaptimmune Therapeutics Financial Overview

Adaptimmune Therapeutics's market cap is currently ―. The company's EPS TTM is $-0.729; its P/E ratio is -1.62; Adaptimmune Therapeutics is scheduled to report earnings on August 7, 2024, and the estimated EPS forecast is $-0.15. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Sep 23Jun 23Mar 23
Income Statement-
Total Revenue$ 5.68M$ 231.00K$ 7.32M$ 5.13M$ 47.60M
Gross Profit$ 5.68M$ 231.00K$ 7.32M$ 5.13M$ 47.60M
EBIT$ -47.98M$ -48.57M$ -44.91M$ -20.71M$ 1.66M
EBITDA$ -45.17M$ -46.09M$ -42.98M$ -19.22M$ 3.62M
Net Income Common Stockholders$ -48.50M$ -47.92M$ -45.49M$ -21.39M$ 1.04M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 143.65M$ 146.94M$ 161.73M$ 204.71M$ 165.55M
Total Assets$ 258.01M$ 282.62M$ 296.64M$ 342.98M$ 288.08M
Total Debt$ 23.69M$ 25.23M$ 25.60M$ 26.34M$ 22.83M
Net Debt$ -119.96M$ -121.70M$ -136.13M$ -178.37M$ -142.72M
Total Liabilities$ 233.63M$ 243.10M$ 208.51M$ 216.33M$ 204.21M
Stockholders Equity$ 24.38M$ 39.51M$ 88.13M$ 126.65M$ 83.88M
Cash Flow-
Free Cash Flow$ -32.31M$ -14.38M$ -45.45M$ -45.00M$ -39.80M
Operating Cash Flow$ -31.95M$ -14.68M$ -45.16M$ -43.76M$ -37.28M
Investing Cash Flow$ -358.00K$ 68.20M$ 57.31M$ 2.69M$ 48.34M
Financing Cash Flow$ 29.23M$ 74.00K$ 596.00K$ 14.00K$ 196.00K
Currency in USD

Adaptimmune Therapeutics Earnings and Revenue History

Adaptimmune Therapeutics Debt to Assets

Adaptimmune Therapeutics Cash Flow

Adaptimmune Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis